Cargando…
Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study
AIMS: Within the past few years, there has been tremendous growth in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. Unlike those of many small-molecule pharmaceuticals, CAR T-cell therapy clinical trials are fraught with risks due to the use of live cell products. The aim of th...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580145/ https://www.ncbi.nlm.nih.gov/pubmed/33149770 http://dx.doi.org/10.1177/1758835920966574 |